Hunt Ronald reported option exercise involving 14,305 derivative units of Rallybio Corp at $3.60 for −$51.5k on Nov 4, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Nov 5, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
−$51,498Shares × reported price
Shares traded
14,305Option (Right to Buy)
Price per share
$3.60Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Nov 4, 2026Option exercise
Filed
Nov 5, 2026, 5:03 PM ET1-day reporting delay
Accession
0001193125-26-450102Code M · Transaction 393725
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 4, 2026Option exercise14,305$4.45$63,657.25Trade 393724
2 transaction rows in this filing. Joint filers share the same rows.

RLYB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RLYB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +7.7%1w ago +1.9%1d ago +1.1%
Returns since7d −0.3%30d90d180d1y

Footnotes in full

F1: The option is granted under the Company's 2021 Equity Incentive Plan. On October 26, 2026, the vesting of the option was accelerated in full, and the option became fully vested and exercisable as of that date. F2: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.